Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: Preliminary results of a feasibility-phase II study aimed at cardiotoxicity

Cecilia Nisticò, Emilio Bria, Vanja Vaccaro, Federica Cuppone, Monica Fornier, Isabella Sperduti, Armando Carpino, Fiorentino Lzzo, Francesco Tropea, Francesco Cognetti, Edmondo Terzoli

Research output: Contribution to journalArticle

Abstract

A feasibility-phase II study was conducted to assess the cardiotoxicity of weekly trastuzumab, epirubicin, and paclitaxel in patients with human epidermal growth factor receptor-2-positive metastatic breast cancer. Untreated patients with human epidermal growth factor receptor-2-positive advanced breast cancer received trastuzumab (day 1), and epirubicin (25 mg/m2) and paclitaxel (80 mg/m2) (day 2) on a weekly basis. The rate of patients with left-ventricular ejection fraction (L-VEF) reduction greater than 10% after 12 weeks was the primary end point According to a two-stage model, an initial step with 15 patients was required; after 11 patients without toxicity, a second step with 21 patients was planned. After 255 courses in 15 patients (median treatment weeks: 18), the relative dose intensity was 94.7%. At 12 weeks, three patients (20%) displayed a L-VEF reduction greater than 10%, six and six (40%) patients showed a L-VEF reduction ≤ 10% or no change, respectively. Baseline, -12 weeks, and - 24 weeks median L-VEF was 69% (range 61 -77), 65% (range 60-76), and 65% (range 55-73), respectively. No EKG/cardiac signs were present. Thirteen patients had grade 3 alopecia and two patients had grade 3 asthenia, in the absence of severe hematological toxicity. Objective responses were observed in 11 patients (73.3%, 95% confidence interval 51.0-95.7), with 10 partial. The weekly administration of trastuzumab- epirubicin-paclitaxel is extremely tolerable, also with regard to L-VEF reduction. These results allowed entrance to the second step of the study.

Original languageEnglish
Pages (from-to)109-114
Number of pages6
JournalAnti-Cancer Drugs
Volume20
Issue number2
DOIs
Publication statusPublished - Feb 2009

Fingerprint

Epirubicin
Paclitaxel
Breast Neoplasms
Stroke Volume
Trastuzumab
Cardiotoxicity
Asthenia
Alopecia
Electrocardiography

Keywords

  • Cardiotoxicity
  • Metastatic breast cancer
  • Trastuzumab
  • Weekly

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer : Preliminary results of a feasibility-phase II study aimed at cardiotoxicity. / Nisticò, Cecilia; Bria, Emilio; Vaccaro, Vanja; Cuppone, Federica; Fornier, Monica; Sperduti, Isabella; Carpino, Armando; Lzzo, Fiorentino; Tropea, Francesco; Cognetti, Francesco; Terzoli, Edmondo.

In: Anti-Cancer Drugs, Vol. 20, No. 2, 02.2009, p. 109-114.

Research output: Contribution to journalArticle

Nisticò, Cecilia ; Bria, Emilio ; Vaccaro, Vanja ; Cuppone, Federica ; Fornier, Monica ; Sperduti, Isabella ; Carpino, Armando ; Lzzo, Fiorentino ; Tropea, Francesco ; Cognetti, Francesco ; Terzoli, Edmondo. / Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer : Preliminary results of a feasibility-phase II study aimed at cardiotoxicity. In: Anti-Cancer Drugs. 2009 ; Vol. 20, No. 2. pp. 109-114.
@article{2e554cd1dfd04fb1bb8d1fc2a0e52e6a,
title = "Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: Preliminary results of a feasibility-phase II study aimed at cardiotoxicity",
abstract = "A feasibility-phase II study was conducted to assess the cardiotoxicity of weekly trastuzumab, epirubicin, and paclitaxel in patients with human epidermal growth factor receptor-2-positive metastatic breast cancer. Untreated patients with human epidermal growth factor receptor-2-positive advanced breast cancer received trastuzumab (day 1), and epirubicin (25 mg/m2) and paclitaxel (80 mg/m2) (day 2) on a weekly basis. The rate of patients with left-ventricular ejection fraction (L-VEF) reduction greater than 10{\%} after 12 weeks was the primary end point According to a two-stage model, an initial step with 15 patients was required; after 11 patients without toxicity, a second step with 21 patients was planned. After 255 courses in 15 patients (median treatment weeks: 18), the relative dose intensity was 94.7{\%}. At 12 weeks, three patients (20{\%}) displayed a L-VEF reduction greater than 10{\%}, six and six (40{\%}) patients showed a L-VEF reduction ≤ 10{\%} or no change, respectively. Baseline, -12 weeks, and - 24 weeks median L-VEF was 69{\%} (range 61 -77), 65{\%} (range 60-76), and 65{\%} (range 55-73), respectively. No EKG/cardiac signs were present. Thirteen patients had grade 3 alopecia and two patients had grade 3 asthenia, in the absence of severe hematological toxicity. Objective responses were observed in 11 patients (73.3{\%}, 95{\%} confidence interval 51.0-95.7), with 10 partial. The weekly administration of trastuzumab- epirubicin-paclitaxel is extremely tolerable, also with regard to L-VEF reduction. These results allowed entrance to the second step of the study.",
keywords = "Cardiotoxicity, Metastatic breast cancer, Trastuzumab, Weekly",
author = "Cecilia Nistic{\`o} and Emilio Bria and Vanja Vaccaro and Federica Cuppone and Monica Fornier and Isabella Sperduti and Armando Carpino and Fiorentino Lzzo and Francesco Tropea and Francesco Cognetti and Edmondo Terzoli",
year = "2009",
month = "2",
doi = "10.1097/CAD.0b013e32831bc09b",
language = "English",
volume = "20",
pages = "109--114",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer

T2 - Preliminary results of a feasibility-phase II study aimed at cardiotoxicity

AU - Nisticò, Cecilia

AU - Bria, Emilio

AU - Vaccaro, Vanja

AU - Cuppone, Federica

AU - Fornier, Monica

AU - Sperduti, Isabella

AU - Carpino, Armando

AU - Lzzo, Fiorentino

AU - Tropea, Francesco

AU - Cognetti, Francesco

AU - Terzoli, Edmondo

PY - 2009/2

Y1 - 2009/2

N2 - A feasibility-phase II study was conducted to assess the cardiotoxicity of weekly trastuzumab, epirubicin, and paclitaxel in patients with human epidermal growth factor receptor-2-positive metastatic breast cancer. Untreated patients with human epidermal growth factor receptor-2-positive advanced breast cancer received trastuzumab (day 1), and epirubicin (25 mg/m2) and paclitaxel (80 mg/m2) (day 2) on a weekly basis. The rate of patients with left-ventricular ejection fraction (L-VEF) reduction greater than 10% after 12 weeks was the primary end point According to a two-stage model, an initial step with 15 patients was required; after 11 patients without toxicity, a second step with 21 patients was planned. After 255 courses in 15 patients (median treatment weeks: 18), the relative dose intensity was 94.7%. At 12 weeks, three patients (20%) displayed a L-VEF reduction greater than 10%, six and six (40%) patients showed a L-VEF reduction ≤ 10% or no change, respectively. Baseline, -12 weeks, and - 24 weeks median L-VEF was 69% (range 61 -77), 65% (range 60-76), and 65% (range 55-73), respectively. No EKG/cardiac signs were present. Thirteen patients had grade 3 alopecia and two patients had grade 3 asthenia, in the absence of severe hematological toxicity. Objective responses were observed in 11 patients (73.3%, 95% confidence interval 51.0-95.7), with 10 partial. The weekly administration of trastuzumab- epirubicin-paclitaxel is extremely tolerable, also with regard to L-VEF reduction. These results allowed entrance to the second step of the study.

AB - A feasibility-phase II study was conducted to assess the cardiotoxicity of weekly trastuzumab, epirubicin, and paclitaxel in patients with human epidermal growth factor receptor-2-positive metastatic breast cancer. Untreated patients with human epidermal growth factor receptor-2-positive advanced breast cancer received trastuzumab (day 1), and epirubicin (25 mg/m2) and paclitaxel (80 mg/m2) (day 2) on a weekly basis. The rate of patients with left-ventricular ejection fraction (L-VEF) reduction greater than 10% after 12 weeks was the primary end point According to a two-stage model, an initial step with 15 patients was required; after 11 patients without toxicity, a second step with 21 patients was planned. After 255 courses in 15 patients (median treatment weeks: 18), the relative dose intensity was 94.7%. At 12 weeks, three patients (20%) displayed a L-VEF reduction greater than 10%, six and six (40%) patients showed a L-VEF reduction ≤ 10% or no change, respectively. Baseline, -12 weeks, and - 24 weeks median L-VEF was 69% (range 61 -77), 65% (range 60-76), and 65% (range 55-73), respectively. No EKG/cardiac signs were present. Thirteen patients had grade 3 alopecia and two patients had grade 3 asthenia, in the absence of severe hematological toxicity. Objective responses were observed in 11 patients (73.3%, 95% confidence interval 51.0-95.7), with 10 partial. The weekly administration of trastuzumab- epirubicin-paclitaxel is extremely tolerable, also with regard to L-VEF reduction. These results allowed entrance to the second step of the study.

KW - Cardiotoxicity

KW - Metastatic breast cancer

KW - Trastuzumab

KW - Weekly

UR - http://www.scopus.com/inward/record.url?scp=59449105698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59449105698&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e32831bc09b

DO - 10.1097/CAD.0b013e32831bc09b

M3 - Article

C2 - 19209027

AN - SCOPUS:59449105698

VL - 20

SP - 109

EP - 114

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 2

ER -